<DOC>
	<DOCNO>NCT00238992</DOCNO>
	<brief_summary>All patient core study interested treat EC-MPS include open-label extension study collect information long-term safety , tolerability efficacy drug . The purpose study evaluate feasibility steroid withdrawal set immunosuppression combination EC-MPS , cyclosporine steroid de novo kidney allograft recipient .</brief_summary>
	<brief_title>Study Enteric-coated Mycophenolate Sodium ( EC-MPS ) With Steroid Withdrawal vs EC-MPS With Standard Steroid Regimen de Novo Renal Transplant Recipients .</brief_title>
	<detailed_description />
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Inclusion Criteria Male female patient undergo first kidney transplant . Patients age 18 70 year . Patients receive ABO identical compatible graft . Exclusion Criteria Multiorgan recipient ( e.g . kidney pancreas ) previous transplant organ kidney . Positive HBsAg test PreTransplant PRA &gt; 50 % historical PRA &gt; 75 % Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Kidney , de novo transplant , steroid withdrawal , adult , EC-MPS cyclosporine</keyword>
</DOC>